-
During 2001 to 2010, 52,644 cases were reported into the national AFP surveillance system, among which, 76 AFP cases were 15 years and older; 2,581 did not have 60 day follow-up examination information; 3,609 had negative stool isolation results but did not have qualified stool samples; 8 had stool samples collected but which were not sent for laboratory analysis; and 649 did not have stool samples. A total of 4,266 cases were excluded from analysis. Among the remaining 45,721 AFP cases were 68 cases of AFP with RP and 100 cases of AFP without RP from which both PV and NPEV were isolated.
The overall annual incidence of AFP with RP ranged from 0.22 to 0.35 per 100,000 children <15 years of age and from 0.02 to 0.05 per 100,000 and 0.02 to 0.08 per 100,000 for AFP with RP from which PV and NPEV were isolated, respectively. Table 1 and Figure 1A–1C show this information on an annual basis. AFP with RP decreased over time, as did the PV isolation rate.
Year AFP cases with RP AFP cases without RP Total AFP cases Incidence of AFP cases having RP (per 100,000)* N (% in AFP cases) Identification of isolates (isolated rate %) N (% in AFP cases) Identification of isolates (isolated rate %) Total With PV isolate With NPEV isolate PV NPEV PV NPEV 2001 1,017 (21.5) 182 (17.9) 94 (9.2) 3,718 (78.5) 182 (4.9) 379 (10.2) 4,735 0.35 0.03 0.06 2002 999 (21.0) 218 (21.8) 97 (9.7) 3,761 (79.0) 211 (5.6) 382 (10.2) 4,760 0.35 0.03 0.08 2003 918 (20.8) 153 (16.7) 101 (11.0) 3,498 (79.2) 193 (5.5) 356 (10.2) 4,416 0.32 0.04 0.05 2004 831 (18.5) 143 (17.2) 95 (11.4) 3,672 (81.5) 156 (4.2) 415 (11.3) 4,503 0.29 0.03 0.05 2005 832 (17.7) 146 (17.5) 93 (11.2) 3,863 (82.3) 134 (3.5) 453 (11.7) 4,695 0.30 0.03 0.05 2006 782 (16.0) 113 (14.5) 101 (12.9) 4,097 (84.0) 130 (3.2) 503 (12.3) 4,879 0.28 0.04 0.04 2007 666 (15.6) 84 (12.6) 69 (10.4) 3,613 (84.4) 103 (2.9) 377 (10.4) 4,279 0.24 0.02 0.03 2008 718 (16.1) 86 (12.0) 101 (14.1) 3,735 (83.9) 90 (2.4) 456 (12.2) 4,453 0.26 0.04 0.03 2009 621 (14.2) 80 (12.9) 94 (15.1) 3,750 (85.8) 72 (1.9) 496 (13.2) 4,371 0.22 0.03 0.03 2010 701 (15.1) 64 (9.1) 144 (20.5) 3,929 (84.9) 75 (1.9) 510 (13.0) 4,630 0.25 0.05 0.02 Total 8,085 (17.7) 1,269 (15.7) 989 (12.2) 37,636 (82.3) 1,346 (3.6) 4,327 (11.5) 45,721 –† –† –† * Population aged <15 years nationwide were used as denominator to calculate the incidences.
† not calculate.
Abbreviations: AFP=acute flaccid paralysis; PV=Sabin-poliovirus; NPEV=Non-Polio Enterovirus; RP=residual paralysis.Table 1. AFP with/without RP and with PV/NPEV isolates by year.
Figure 1.Distribution of paralysis onset in AFP cases with/without residual paralysis during 2001–2010.
(A) Monthly distribution of paralysis onset in AFP cases with RP during 2001–2010. (B) Monthly distribution of paralysis onset in AFP cases without RP during 2001–2010. (C) Yearly distribution of paralysis onset in AFP case, with/without RP and with PV/NPEV isolates during 2001–2010. (D) Monthly distribution of paralysis onset in AFP case, with/without RP and with PV/NPEV isolates during 2001–2010. (E) Age distribution of <5 year old AFP case with/without residual paralysis and with PV/NPEV isolates during 2001–2010. Abbreviations: AFP=acute flaccid paralysis; RP=residual paralysis; PV=Sabin-poliovirus; NPEV=Non-Polio Enteroviruse.NPEV isolation rates did not decrease during this time. The PV isolation rate was higher in AFP with RP (15.7%) than in AFP without RP (3.6%). In AFP with RP, the number of cases with PV isolates was slightly larger than cases with NPEV isolates (1,269∶989). In contrast, the number of cases of AFP without RP and with PV isolates was much smaller than the number of cases with NPEV isolates (1,346∶4,327).
AFP cases with RP peaked in the summer season from May to August, compared with AFP cases without RP which was relatively constant throughout the year (Figure 1A–1B). For AFP with PV isolates, the number of cases increased at the end and beginning of the years (Figure 1D).
AFP cases below 5 years of age accounted for 94.7% of AFP cases in which RP and PV were isolated, 76.6% in which AFP with RP and NPEV were isolated, 88.1% in which AFP without RP with PV were isolated, and 81.6% in which AFP without RP but with NPEV were isolated. In AFP with RP and PV isolates, the sharp peak of onset occurred in children aged 2–4 months old. The age distribution of AFP without RP with PV isolated did not show a peak (Figure 1E).
The sex distribution showed that 61.5%–67.4% of cases were male in all 4 categories.
In AFP with PV isolated, the number of cases of AFP with RP was similar to that of AFP without RP (1,266∶1,346), infants <6 months old constituted 23% of AFP cases with RP, about 2 times the number of AFP without RP. For AFP with RP and PV isolates, 81.3% had fever before paralysis onset, a percent that was greater than in the other 3 categories (52.1%–56.3%). Among the 3 types of PV, type II, followed by type III, had the highest isolation rates of AFP with RP, especially among cases with a 0-dose OPV history (19.0%) (Tables 2–3).
Approximately one-third of AFP cases with RP had diagnoses as “other,” which was the most common diagnostic category. Among these cases, PV was isolated in 39.3% and NPEV was isolated in 29.0%. Another 15.8% and 8.8% had no final diagnosis information for PV and NPEV isolates, respectively. GBS constituted the second largest diagnostic category (Table 3).
OPV history RP No. of cases (isolated rate %) by serotype Non-RP No. of cases (isolated rate %) by serotype Ⅰ Ⅱ Ⅲ Ⅰ Ⅱ Ⅲ 0 dose 34 (2.8) 230 (19.0) 95 (7.9) 9 (0.7) 103 (8.5) 35 (2.9) 1 dose 89 (5.4) 236 (14.3) 172 (10.4) 52 (3.1) 123 (7.4) 83 (5) 2 doses 46 (2.6) 79 (4.4) 70 (3.9) 47 (2.6) 73 (4.1) 59 (3.3) ≥3 doses 100 (0.3) 183 (0.5) 137 (0.4) 348 (0.9) 392 (1) 344 (0.9) Unknown 13 (0.4) 44 (1.3) 29 (0.9) 19 (0.6) 35 (1.1) 20 (0.6) Vacancy 0 (0.0) 6 (1.4) 2 (0.5) 6 (1.4) 6 (1.4) 5 (1.1) Abbreviations: AFP=acute flaccid paralysis; RP=residual paralysis; OPV=oral poliovirus vaccine. Table 2. Three types of Sabin-like poliovirus isolates in AFP case with/without RP and with different OPV history during 2001–2010.
Item RP(%) No* RP(%) Item RP(%) No RP(%) PV NPEV PV NPEV PV NPEV PV NPEV Gender† OPV history Male 855(67.4) 608(61.5) 892(66.3) 2,893(66.9) 0 dose 318(25.1) 50(5.1) 127(9.4) 100(2.3) Female 414(32.6) 381(38.5) 454(33.7) 1,433(33.1) 1 dose 369(29.1) 51(5.2) 187(13.9) 95(2.2) Age group (month) 2 doses 150(11.8) 77(7.8) 140(10.4) 179(4.1) 0–5 296(23.3) 49(5.0) 161(12) 71(1.6) ≥3 doses 350(27.6) 728(73.6) 817(60.7) 3,723(86.0) 6–11 255(20.1) 107(10.8) 143(10.6) 226(5.2) Unknown 75(5.9) 74(7.5) 63(4.7) 202(4.7) 12–47 634(50.0) 547(55.3) 838(62.3) 2,996(69.2) Vacancy 7(0.6) 9(0.9) 12(0.9) 28(0.6) 48– 81(6.4) 285(28.8) 204(15.2) 1,031(23.8) Interval¶ Wrongly filled§ 3(0.2) 1(0.1) 0(0.0) 3(0.1) 6–40D 347(27.3) 51(5.2) 243(18.1) 186(4.3) Fever history <6D 340(26.8) 342(34.6) 517(38.4) 1,055(24.4) Fever 1,032(81.3) 557(56.3) 753(55.9) 2,255(52.1) >40D 264(20.8) 546(55.2) 459(34.1) 2,986(69) No-fever 225(17.7) 420(42.5) 587(43.6) 2,048(47.3) No/Unknown** 318(25.1) 50(5.1) 127(9.4) 100(2.3) Unknown 11(0.9) 12(1.2) 6(0.4) 23(0.5) PV isolates Vacancy 1(0.1) 0(0.0) 0(0.0) 1(0.0) Ⅰ 140(11.0) 11(1.1) 243(18.1) 19(0.4) Final diagnosis Ⅱ 559(44.1) 30(3.0) 474(35.2) 40(0.9) GBS 274(21.6) 337(34.1) 247(18.4) 834(19.3) Ⅲ 310(24.4) 16(1.6) 293(21.8) 22(0.5) NPEV 47(3.7) 120(12.1) 71(5.3) 595(13.8) Ⅰ+Ⅱ 65(5.1) 2(0.2) 83(6.2) 5(0.1) Transverse myelitis 51(4.0) 43(4.3) 32(2.4) 114(2.6) Ⅰ+Ⅲ 41(3.2) 4(0.4) 78(5.8) 5(0.1) Traumatic neuritis 197(15.5) 115(11.6) 244(18.1) 653(15.1) Ⅱ+Ⅲ 118(9.3) 3(0.3) 98(7.3) 5(0.1) Other 499(39.3) 287(29.0) 543(40.3) 1,468(33.9) Ⅰ+Ⅱ+Ⅲ 36(2.8) 2(0.2) 77(5.7) 4(0.1) Vacancy 201(15.8) 87(8.8) 209(15.5) 663(15.3) NPEV isolates NPEV 68(5.4) 989(100) 100(7.4) 4,327(100) Negative 1,201(94.6) 0(0.0) 1,246(92.6) 0(0) * “None” only calculate the result from stools regarded as “adequate”;
† The information of gender in 1 AFP belonged to “Non-residual paralysis” and no enterovirus isolates cases was “unknown”;
§ Wrongly filled: the filled date of illness onset was prior to birth date;
¶ Interval: Time interval between vaccination and paralysis onset in days;
** No/Unknown: with no OPV vaccination history or unknown OPV vaccination status;
Abbreviations: AFP=acute flaccid paralysis; PV=Sabin-poliovirus; NPEV=Non-Polio Enterovirus; RP= residual paralysis; OPV=oral poliovirus vaccine.Table 3. Demographic features of AFP case with/without RP and with PV/NPEV isolates during 2001–2010.
HTML
Citation: |